

PROGRAM

PROGRAM

AMERICAN PSYCHIATRIC ASSOCIATION 2007 ANNUAL MEETING



ADDRESSING PATIENT NEEDS
ACCESS, PARITY AND HUMANE CARE

160TH ANNUAL MEETING
SAN DIEGO, CALIFORNIA, MAY 19-24, 2007
AMERICAN PSYCHIATRIC
ASSOCIATION

SAN DIEGO, CA ♦ MAY 19-24, 2007

AMERICAN PSYCHIATRIC ASSOCIATION CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

Under the ACCME Standards for Commercial Support that were in effect when the 2007 Annual Meeting was planned, the existence of such relationships does not necessarily constitute a conflict of interest; but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter's name and the company's name are listed, along with the page number the presenter appears on in this *Program Book*. The nature of the presenter's relationship with the disclosed company is indicated by the following code: consultant or advisory board¹, full-time employment², research/grant support³, speakers' bureau⁴, stock or other financial options⁵, other financial or business relationships⁶. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

The second list of presenters, beginning on page ****, have indicated neither they nor an immediate family member has any significant relationship to disclose. Voting member of the Board of Trustees, Assembly officers, and member of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia.

Presenter	Manufacturer(s)
Gene G. Abel, M.D.	Abel Screening, Inc. ⁶
Hagop S. Akiskal, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ^{3,5} ; Eli Lilly and Company ^{3,5} ; GlaxoSmithKline ^{1,3,5} ; Sanofi-Aventis ^{1,5}
Michael H. Allen, M.D.	Abbott Laboratories, Inc. ^{1,3} ; Alexza MDC ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ^{1,3}
Jonathan E. Alpert, M.D.	Abbott Laboratories, Inc. ³ ; Alkermes, Inc. ³ ; Aspect Medical Systems ³ ; AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Cephalon, Inc. ³ ; Cyberonics, Inc. ³ ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Johnson & Johnson ³ ; Johnson and Johnson Pharmaceutical Research and Development ³ ; Lichtwer Pharma GmbH ³ ; Lorex Pharmaceuticals ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ³ ; Organon Pharmaceuticals Inc. ^{3,5} ; PamLab ^{1,3} ; Pfizer Inc. ³ ; Pharmavite ^{1,3} ; Roche Pharmaceuticals ³ ; Sanofi/Synthelabo ³ ; Sanofi-Aventis ³ ; Solvay Pharmaceuticals, Inc. ³ ; Wyeth-Ayerst Laboratories ³
Lori L. Altshuler, M.D.	Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals LP ^{4,5} ; Bristol-Myers Squibb Company ^{1,4,5} ; Eli Lilly and Company ^{1,4,5} ; Forest Laboratories, Inc. ^{1,4} ; GlaxoSmithKline ^{4,5} ; Pfizer Inc. ^{1,4} ; Wyeth Pharmaceuticals ⁴
Sonia Ancoli-Israel, Ph.D.	Acadia Pharmaceuticals Inc. ¹ ; Cephalon, Inc. ^{1,5} ; King Pharmaceuticals, Inc. ^{1,5} ; Merck & Co., Inc. ¹ ; Neurocrine Biosciences Inc. ^{1,5} ; Neurogen Corporation ¹ ; NIH Institute ³ ; Pfizer Inc. ^{1,5} ; Sanofi-Aventis ^{1,5} ; Sepracor, Inc. ^{1,5} ; Takeda Pharmaceuticals America, Inc. ^{1,5}
Raymond F. Anton, M.D.	Alkermes, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ³ ; Cephalon, Inc. ^{1,5} ; Forest Laboratories, Inc. ^{1,3} ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ³
William J. Apfeldorf, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵ ; Eisai Inc. ³ ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ^{1,5} ; Janssen Pharmaceutica Products, LP ⁵ ; Pfizer Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Lesley M. Arnold, M.D.	Cypress Bioscience Inc. ^{1,3} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ¹ ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ^{1,3} ; Sepracor, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,5}
Alan Axelson, M.D.	Eli Lilly and Company ⁵ ; Novartis Pharmaceuticals Corporation ⁵ ; Shire Pharmaceuticals Group plc. ⁵
Marion A. Becker, Ph.D.	Eli Lilly and Company ³
Julian Beezhold, M.B.Ch.B.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ⁵ ; Janssen-Cilag ⁵
Bernard D. Beitman, M.D.	Bristol-Myers Squibb Company ⁵
Ruth M. Benca, M.D.	GlaxoSmithKline ¹ ; Neurocrine Biosciences Inc. ^{1,5} ; Pfizer Inc. ^{1,5} ; Sanofi-Aventis ^{1,5} ; Sepracor, Inc. ^{1,5} ; Takeda Pharmaceuticals America, Inc. ^{1,5} ; Wyeth Pharmaceuticals ⁵
Donna S. Bender, Ph.D.	National Institute of Mental Health ³
Susan R. Bergeson, M.B.A.	Abbott Laboratories, Inc. ³

Presenter	Manufacturer(s)
John L. Beyer, M.D.	Avanir Pharmaceuticals ¹ ; Bristol-Myers Squibb Company ^{3,5} ; Eisai Inc. ³ ; Elan Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ^{3,5} ; Janssen Pharmaceutica Products, LP ⁵ ; Myriad Genetics, Inc. ³ ; Pfizer Inc. ³
Joseph Biederman, M.D.	Abbott Laboratories, Inc. ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Cephalon, Inc. ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3} ; McNeil Consumer Healthcare ^{1,3,5} ; National Institute of Child Health and Human Development ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; NRP ³ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3,5} ; Pfizer Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ^{1,3,5} ; Stanley Medical Research Institute ³ ; UCB Pharma ^{1,5}
Adam Bisaga, M.D.	Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ¹
Donald W. Black, M.D.	Forest Laboratories, Inc. ^{1,3,5} ; Pfizer Inc. ⁵ ; Scirex Corporation ⁵ ; Shire Pharmaceuticals Group plc. ^{1,2,3,5}
Carlos Blanco-Jerez, M.D.	Somaxon Pharmaceuticals ³
Barton J. Blinder, M.D.	Pfizer Inc. ³
Paul B. Bohn, M.D.	Forest Laboratories, Inc. ⁵ ; Pfizer Inc. ⁵ ; Wyeth-Ayerst Laboratories ⁵
Curley L. Bonds, M.D.	Abbott Laboratories, Inc. ⁵ ; Pfizer Inc. ⁵
Howard E. Book, M.D.	American Psychological Association Press ⁴
Charles L. Bowden, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ³ ; Elan Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Johnson and Johnson Pharmaceutical Research and Development ³ ; National Institute of Mental Health ³ ; Parke-Davis ³ ; Pfizer Inc. ⁵ ; Stanley Medical Research Institute ³ ; UCB Pharma ¹
Kathleen T. Brady, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; Alkermes, Inc. ¹ ; Cephalon, Inc. ¹ ; Eli Lilly and Company ^{1,5} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; National Institute on Drug Abuse ^{1,3} ; Ovation Pharmaceuticals, Inc. ¹ ; Pfizer Inc. ^{1,5} ; Wyeth Pharmaceuticals ³
Ronald Brenner, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ⁵
Thomas E. Brown, Ph.D.	American Psychiatric Press ⁴ ; Cephalon, Inc. ¹ ; Eli Lilly and Company ^{1,3} ; McNeil Consumer Healthcare ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Shire Pharmaceuticals Group plc. ^{1,3}
Peter F. Buckley, M.D.	Abbott Laboratories, Inc. ^{1,5} ; Alamo Pharmaceuticals ^{1,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Merck & Co., Inc. ¹ ; National Institute of Mental Health ³ ; Pfizer Inc. ^{1,3,5} ; Solvay Pharmaceuticals, Inc. ³
Stephen E. Buie, M.D.	Wyeth Pharmaceuticals ⁵
Oscar G. Bukstein	Cephalon, Inc. ¹ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ¹ ; Novartis Pharmaceuticals Corporation ⁵ ; Ortho-McNeil Pharmaceutical, Inc. ⁵ ; Sanofi-Aventis ³ ; Shire Pharmaceuticals Group plc. ^{1,3,5}
Harold L. Burke, Ph.D.	EEG Spectrum International, Inc. ^{2,6}
George Bush, M.D.	Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ⁵ ; Johnson and Johnson Pharmaceutical Research and Development ⁵ ; McNeil Consumer Healthcare ^{3,5} ; Novartis Pharmaceuticals Corporation ⁵ ; Pfizer Inc. ³ ; Shire Pharmaceuticals Group plc. ⁵
Daniel J. Buysse, M.D.	Cephalon, Inc. ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Merck & Co., Inc. ¹ ; Merck, Sharp, and Dohme ¹ ; Neurocrine Biosciences Inc. ¹ ; Neurogen Corporation ¹ ; Pfizer Inc. ^{1,3} ; Respironics, Inc. ¹ ; Sanofi-Aventis ^{1,3} ; Sepracor, Inc. ^{1,3} ; Servier ¹ ; Takeda Pharmaceuticals America, Inc. ^{1,3}
Nancy Byatt, D.O.	AstraZeneca Pharmaceuticals LP ³ ; Eli Lilly and Company ³
Joseph R. Calabrese, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Merck & Co., Inc. ³ ; Teva Pharmaceutical Industries Ltd. ¹
William E. Callahan, Jr., M.D.	Bristol-Myers Squibb Company ⁵ ; Otsuka America Pharmaceutical, Inc. ⁵
William H. Campbell, M.D.	Pfizer Inc. ⁵ ; Sanofi-Aventis ⁵
Joseph Cappelleri	Pfizer Inc. ²
Stanley N. Caroff, M.D.	Bristol-Myers Squibb Company ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ³
William T. Carpenter, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Cephalon, Inc. ¹ ; Lilly ¹ ; National Institute of Mental Health ^{1,3} ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Diana Carter, M.B.B.S.	GlaxoSmithKline ⁵ ; Wyeth Pharmaceuticals ³
Daniel E. Casey, M.D.	Abbott Laboratories, Inc. ^{1,5} ; Bristol-Myers Squibb Company ^{1,5} ; Janssen Pharmaceutica Products, LP ^{1,5} ; Pfizer Inc. ^{1,5} ; Solvay Pharmaceuticals, Inc. ¹ ; Sumitomo Pharmaceuticals Co., Ltd ¹ ; Wyeth Pharmaceuticals ¹
David A. Casey, M.D.	Abbott Laboratories, Inc. ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; Pfizer Inc. ⁵
Alfonso Ceccherini-Nelli, M.D.	GlaxoSmithKline ²
Robert A. Chambers, M.D.	Forest Laboratories, Inc. ⁵ ; National Institute on Drug Abuse ³
Kiki D. Chang, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ^{1,3} ; Lilly ¹ ; Otsuka America Pharmaceutical, Inc. ³ ; Shire Pharmaceuticals Group plc. ¹

Presenter	Manufacturer(s)
Joseph A. Cheong, M.D.	AstraZeneca Pharmaceuticals LP ⁵
Allen Childs, M.D.	Abbott Laboratories, Inc. ¹
Lois W. Choi-Kain, M.D.	National Institute of Mental Health ³
Henry Chung, M.D.	National Institute of Mental Health ³ ; Pfizer Inc. ⁵
Leslie L. Citrome, M.D.	Abbott Laboratories, Inc. ^{5,6} ; AstraZeneca Pharmaceuticals LP ^{3,5} ; Bristol-Myers Squibb Company ^{1,3,6} ; Eli Lilly and Company ^{1,3,5,6} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ³ ; Jazz Pharmaceuticals, Inc. ¹ ; Johnson and Johnson Pharmaceutical Research and Development ⁶ ; Merck & Co., Inc. ⁶ ; Pfizer Inc. ^{1,3,5,6}
Daniel J. Clauw, M.D.	Cypress Bioscience Inc. ^{1,6}
Anita L. Clayton, M.D.	Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ^{1,3,5} ; Neuronetics, Inc. ³ ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ³ ; Vela Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3,5}
Emil F. Coccaro, M.D.	Abbott Laboratories, Inc. ^{1,3} ; Eli Lilly and Company ³ ; Pfizer Inc. ¹
Judith A. Cohen	Department of Health and Human Services ³ ; Guilford Press ⁴ ; National Institute of Mental Health ³
Francesc Colom, Ph.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Lilly ⁵ ; Sanofi-Aventis ⁵
David O. Conant-Norville, M.D.	McNeil Consumer Healthcare ⁵ ; Novartis Pharmaceuticals Corporation ⁵
Daniel F. Connor, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Cephalon, Inc. ⁵ ; Shire Pharmaceuticals Group plc. ⁵
Ram Cooppan, M.B.Ch.B.	Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ⁵ ; Novartis Pharmaceuticals Corporation ⁵ ; Novo Nordisk Pharmaceuticals, Inc. ⁵ ; Pfizer Inc. ⁵ ; Sanofi-Aventis ⁵ ; Takeda Pharmaceuticals America, Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Gabriela Cora-Locatelli, M.D.	Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Pfizer Inc. ¹
Barbara A. Cornblatt, Ph.D.	Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ³
Maria R. Corral, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Janssen Pharmaceutica Products, LP ³
Christoph U. Correll, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,5} ; Eli Lilly and Company ¹ ; Healthcare Technology Systems, Inc. ¹ ; Intra-Cellular Therapeutics ¹ ; Janssen Pharmaceutica Products, LP ⁵
Leslie J. Crofford, M.D.	Allergan Inc. ¹ ; Cypress Bioscience Inc. ¹ ; Merck, Sharp, and Dohme ¹ ; Orphan Medical ¹ ; Pfizer Inc. ^{1,3} ; Wyeth Pharmaceuticals ^{1,3}
Jeffrey L. Cummings, M.D.	Abbott Laboratories, Inc. ¹ ; Eisai Inc. ⁵
Daniella David, M.D.	Janssen Pharmaceutica Products, LP ³
Jonathan S. Davine, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Biovail Corporation ⁵ ; Wyeth Pharmaceuticals ⁵
Lori L. Davis, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Cyberonics, Inc. ^{1,5} ; Eisai Inc. ³ ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health ³
Melissa P. DelBello, M.D.	Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ⁵ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3} ; Otsuka America Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{1,5}
Pedro L. Delgado, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Corcept Therapeutics ³ ; Eli Lilly and Company ^{1,5} ; Forest Laboratories, Inc. ^{1,3} ; Medtronic, Inc. ³ ; National Institute of Mental Health ^{1,3} ; Neuronetics, Inc. ¹ ; NIH Institute ^{1,3} ; Pfizer Inc. ⁶ ; Wyeth Pharmaceuticals ^{1,5} ; Wyeth-Ayerst Laboratories ⁵
Davangere P. Devanand	Eli Lilly and Company ³ ; Wyeth Pharmaceuticals ³
C. Lindsay DeVane, Pharm.D.	Bristol-Myers Squibb Company ³ ; Cyberonics, Inc. ³ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; National Institute of Mental Health ³ ; NovaDel Pharma Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3}
Mantosh J. Dewan, M.D.	McNeil Consumer Healthcare ³
Ronald J. Diamond, M.D.	Bristol-Myers Squibb Company ^{1,5} ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ^{1,5} ; Janssen-Cilag ^{1,5} ; Pfizer Inc. ¹
Joel Dimsdale, M.D.	Sepracor, Inc. ³
Lisa Dixon, M.D.	Bristol-Myers Squibb Company ³
Robert K. Dolgoff, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵
P. Murali Doriaswamy, M.D.	Eisai Inc. ³ ; Elan Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ^{1,5} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ³ ; Myriad Genetics, Inc. ¹ ; Saegis ¹ ; Sanofi-Aventis ³
Christopher L. Drake, Ph.D.	Cephalon, Inc. ⁵ ; Pfizer Inc. ¹ ; Sepracor, Inc. ^{1,5} ; Takeda Pharmaceuticals America, Inc. ⁵
Ronald S. Duman, Ph.D.	Eli Lilly and Company ³ ; National Foundation for Mental Health ³ ; Organon Pharmaceuticals Inc. ³ ; Sepracor, Inc. ³
Laura B. Dunn, M.D.	National Institute of Mental Health ³
James M. Ellison, M.D.	Bristol-Myers Squibb Company ⁵ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ^{3,5} ; Pfizer Inc. ⁵ ; Wyeth Pharmaceuticals ⁵

Presenter	Manufacturer(s)
Raymond A. Faber	Bristol-Myers Squibb Company ⁵ ; Cephalon, Inc. ⁵ ; Forest Laboratories, Inc. ⁵
Andrea Fagiolini, M.D.	Bristol-Myers Squibb Company ¹ ; GlaxoSmithKline ¹ ; Merck & Co., Inc. ³ ; Pfizer Inc. ³
Warachal E. Faison, M.D.	Bristol-Myers Squibb Company ^{1,5} ; Forest Laboratories, Inc. ^{1,5} ; GlaxoSmithKline ⁴ ; Janssen Pharmaceutica Products, LP ^{1,5} ; National Institute of Mental Health ³ ; National Institute on Aging ³ ; Organon Pharmaceuticals Inc. ³ ; Otsuka America Pharmaceutical, Inc. ^{1,5} ; Pfizer Inc. ^{1,3,5}
Stephen V. Faraone, Ph.D.	Cephalon, Inc. ^{1,5} ; Eli Lilly and Company ^{1,3,5} ; McNeil Consumer Healthcare ^{1,3,5} ; National Foundation for Mental Health ³ ; National Institute of Child Health and Human Development ³ ; National Institute of Mental Health ³ ; National Institute of Neurological Disorders and Stroke ³ ; National Institute on Drug Abuse ³ ; Noven Pharmaceuticals, Inc. ¹ ; Shire Pharmaceuticals Group plc. ^{1,3,5}
Maurizio Fava, M.D.	Abbott Laboratories, Inc. ³ ; Alkermes, Inc. ³ ; Aspect Medical Systems ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bayer Corporation ¹ ; Biovail Corporation ¹ ; Boehringer-Ingelheim Pharmaceuticals ⁵ ; BrainCells, Inc. ¹ ; Bristol-Myers Squibb Company ^{1,3,5} ; Cephalon, Inc. ^{1,3,5} ; Compellis Pharmaceuticals ^{1,6} ; Cypress Bioscience Inc. ¹ ; Cypress Pharmaceuticals ¹ ; Dov Pharmaceuticals ¹ ; Eli Lilly and Company ^{1,3,5} ; EPIX ¹ ; Fabre Kramer Pharmaceuticals Inc. ¹ ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; Grunenthal GmbH ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Jazz Pharmaceuticals, Inc. ¹ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3} ; Knoll Pharmaceutical Company ¹ ; Lichtwer Pharma GmbH ³ ; Lorex Pharmaceuticals ³ ; Lundbeck ¹ ; MedAvante, Inc. ^{1,6} ; Neuronetics, Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; Nutrition 21, Inc. ¹ ; Organon Pharmaceuticals Inc. ^{1,3,5} ; PamLab ^{1,3} ; Pfizer Inc. ^{1,3,5} ; Pharmacia & Upjohn ^{1,3} ; PharmaStar ^{1,5} ; Pharmavite ^{1,3} ; Roche Pharmaceuticals ^{1,3} ; Sanofi/Synthelabo ^{1,3} ; Sanofi-Aventis ^{1,3} ; Sepracor, Inc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Somaxon Pharmaceuticals ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3,5} ; Wyeth-Ayerst Laboratories ^{1,3,5}
Jan Fawcett, M.D.	Abbott Laboratories, Inc. ¹ ; Eli Lilly and Company ⁵ ; National Institute of Mental Health ³ ; Wyeth Pharmaceuticals ¹
Francisco Fernandez, M.D.	Bristol-Myers Squibb Company ³ ; Cyberonics, Inc. ³ ; Esai-Pfizer ³ ; NIH Institute ³ ; Pfizer Inc. ³ ; Sumitomo Pharmaceuticals Co., Ltd ³ ; Wyeth Pharmaceuticals ⁵
Robert L. Findling, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹ ; Sanofi-Aventis ¹ ; Shire Pharmaceuticals Group plc. ^{1,5} ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Naomi A. Fineberg	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ³ ; Cephalon, Inc. ³ ; GlaxoSmithKline ¹
David P. Folsom, M.D.	National Institute of Mental Health ⁴
Timothy W. Fong, M.D.	Forest Laboratories, Inc. ⁵ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Reckitt-Benkiser ⁵
Brent P. Forester, M.D.	Abbott Laboratories, Inc. ^{3,5} ; AstraZeneca Pharmaceuticals LP ⁵ ; Eli Lilly and Company ⁵ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ⁵ ; Novartis Pharmaceuticals Corporation ⁵ ; Pfizer Inc. ^{3,5}
Philippe Fossati, M.D.	Eli Lilly and Company ¹ ; Servier ³
Ellen Frank, Ph.D.	Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ³ ; Forest Research Institute ³ ; Guilford Press ⁴ ; Guilford Pharmaceuticals ¹ ; H. Lundbeck A/S, Guilford Press ⁴ ; Lundbeck ¹ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ¹ ; Servier ¹
Gordon Frankle, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Fujisawa Pharmaceutical, Co. ³
Nancy Frasure-Smith, Ph.D.	GlaxoSmithKline ³ ; IsodisNatura ³ ; Solvay Pharmaceuticals, Inc. ⁵
Marlene P. Freeman, M.D.	Arizona Disease Control Research Commission ³ ; AstraZeneca Pharmaceuticals LP ⁵ ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ⁵ ; Pronova Biocare ³ ; Reliant ¹ ; The Institute for Mental Health Research of Arizona ³ ; THER-X ¹ ; U.S. Food and Drug Administration ³
Fred Frese, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹
Robert D. Friedberg, Ph.D.	Guilford Publications ⁴
Joseph I. Friedman, M.D.	Eli Lilly and Company ³
Mark A. Frye, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; American Foundation for Suicide Prevention ³ ; AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,5} ; Cephalon, Inc. ⁵ ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ^{1,3} ; Indevus Pharmaceuticals, Inc. ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; Janssen-Cilag ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ^{1,5} ; Ortho-McNeil Pharmaceutical, Inc. ¹ ; Otsuka America Pharmaceutical, Inc. ^{1,3,5} ; Pfizer Inc. ^{1,3,5} ; Solvay Pharmaceuticals, Inc. ³ ; Stanley Medical Research Institute ³ ; Wyeth Pharmaceuticals ¹
Kenneth D. Gadow, Ph.D.	Checkmate Plus ⁶
Wolfgang Gaebel, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ¹ ; GlaxoSmithKline ⁵ ; H. Lundbeck A/S ¹ ; Janssen-Cilag ^{1,3,5} ; Lilly ^{1,3,5} ; Lundbeck ^{1,3,5} ; Novartis Pharmaceuticals Corporation ¹ ; Sanofi-Aventis ⁵ ; Wyeth Pharmaceuticals ^{1,3}

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Fred H. Gage, Ph.D.	BrainCells, Inc. ^{1,6} ; Celgene Corporation ⁶ ; Ceregene, Inc. ^{1,6} ; Stem Cells Inc. ^{1,6}
James E. Galvin, M.D.	Eisai Inc. ⁵ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ⁵ ; National Institute of Mental Health ³ ; National Institute on Aging ³ ; Novartis Pharmaceuticals Corporation ⁵ ; Ortho-McNeil Pharmaceutical, Inc. ⁵ ; Pfizer Inc. ⁵
Keming Gao, M.D.	AstraZeneca Pharmaceuticals LP ⁵
Mark S. George, M.D.	Aventis Pharmaceuticals, Inc. ¹ ; Biovail Corporation ³ ; Cortex Pharmaceuticals, Inc. ³ ; Cyberonics, Inc. ^{1,3,5} ; GlaxoSmithKline ³ ; Jazz Pharmaceuticals, Inc. ¹ ; National Institute of Health ³ ; Neuronetics, Inc. ^{1,3} ; NeuroPace, Inc. ^{1,3}
Tony P. George, M.D.	Eli Lilly and Company ⁵ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute on Drug Abuse ³ ; Pfizer Inc. ^{1,5} ; Targacept, Inc. ³
Nassir Ghaemi, M.D.	Abbott Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ³
Mona H. Gill, M.D.	Wyeth Pharmaceuticals ⁵
Michael J. Gitlin	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Cephalon, Inc. ⁵ ; Eli Lilly and Company ⁵ ; GlaxoSmithKline ⁵ ; Pfizer Inc. ⁵
Alexander H. Glassman, M.D.	Pfizer Inc. ⁵
Tasha Glenn, Ph.D.	Chronorecord Association ⁴
Ira D. Glick, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ⁶ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ⁵ ; Johnson and Johnson Pharmaceutical Research and Development ⁶ ; Pfizer Inc. ⁵ ; Shire Pharmaceuticals Group plc. ^{3,5} ; Solvay Pharmaceuticals, Inc. ^{1,3}
Donald C. Goff, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,3,5} ; Cephalon, Inc. ³ ; Eli Lilly and Company ⁵ ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Merck & Co., Inc. ¹ ; Pfizer Inc. ^{1,3,5} ; Wyeth Pharmaceuticals ¹
Harold W. Goforth, M.D.	Bristol-Myers Squibb Company ^{1,5} ; Forest Laboratories, Inc. ³ ; Pfizer Inc. ³ ; Sepracor, Inc. ³
Joseph F. Goldberg, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{3,5} ; Bristol-Myers Squibb Company ^{3,5} ; Eli Lilly and Company ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ^{3,5}
Gabe Goldfeder, M.A.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; Myriad Genetics, Inc. ³ ; Otsuka America Pharmaceutical, Inc. ³ ; Pfizer Inc. ³ ; Sanofi-Aventis ³
Morris B. Goldman, M.D.	National Institute of Mental Health ³ ; Otsuka America Pharmaceutical, Inc. ³ ; Pfizer Inc. ³
Irwin Goldstein	Bayer Corporation ¹ ; Eli Lilly and Company ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Pfizer Inc. ¹ ; Proctor & Gamble Pharmaceuticals, Inc. ¹
Frederick K. Goodwin, M.D.	Abbott Laboratories, Inc. ³ ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ³ ; Solvay Pharmaceuticals, Inc. ³
Jon E. Grant, M.D.	Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Somaxon Pharmaceuticals ^{1,3}
Jack A. Grebb, M.D.	Bristol-Myers Squibb Company ^{2,6}
George T. Grossberg, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Janssen-Cilag ¹ ; Lilly ^{1,3} ; Myriad Genetics, Inc. ³ ; National Institute on Aging ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Ono Pharmaceuticals, Inc. ³ ; Pfizer Inc. ^{1,3} ; Sanofi-Aventis ¹ ; Sepracor, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3}
Linda S. Grossman, Ph.D.	National Institute of Mental Health ³
Heinz Grunze, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5} ; Eli Lilly and Company ⁵ ; GlaxoSmithKline ^{1,5} ; Janssen-Cilag ⁵ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ^{1,5} ; UCB Pharma ³
Sanjay Gupta, M.D.	Abbott Laboratories, Inc. ^{3,6} ; AstraZeneca Pharmaceuticals LP ^{3,5} ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{3,5} ; Johnson and Johnson Pharmaceutical Research and Development ³ ; Memory Pharmaceuticals ³ ; Myriad Genetics, Inc. ³ ; Neurochem, Inc. ³ ; Ono Pharmaceuticals, Inc. ³ ; Otsuka America Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{3,5} ; Solvay Pharmaceuticals, Inc. ³ ; Somaxon Pharmaceuticals ³
Raquel E. Gur, M.D.	NIH Institute ³
Robert E. Hales	Bristol-Myers Squibb Company ^{3,5}
Martin Harrow, Ph.D.	National Institute of Mental Health ³
Philip D. Harvey, Ph.D.	Solvay Pharmaceuticals, Inc., Pfizer Inc. ¹

Presenter	Manufacturer(s)
David Healy, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Teva Pharmaceutical Industries Ltd. ^{1,4}
David J. Hellerstein, M.D.	Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³
David C. Henderson, M.D.	Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ³ ; Pfizer Inc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ¹
Charles H. Hennekens, M.D.	Amgen, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ^{1,5} ; Bayer Corporation ¹ ; Biovail Corporation ¹ ; Bristol-Myers Squibb Company ^{1,5} ; GlaxoSmithKline ¹ ; McNeil Consumer Healthcare ¹ ; Merck & Co., Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ^{1,5} ; Solvay Pharmaceuticals, Inc. ¹ ; TAP Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Jacqueline Henschke, M.D.	AstraZeneca Pharmaceuticals LP ³
Paula L. Hensley, M.D.	Amgen, Inc. ⁴ ; Pfizer Inc. ⁶
Barry K. Herman, M.D.	Pfizer Inc. ⁶
Napoleon B. Higgins, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; GlaxoSmithKline ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; McNeil Consumer Healthcare ⁵ ; Novartis Pharmaceuticals Corporation ⁵ ; Shire Pharmaceuticals Group plc. ⁵
Marynell Hinton, M.A.	Professional Risk Management Services, Inc. ²
Max Hirshkowitz, Ph.D.	Aventis Pharmaceuticals, Inc. ³ ; Cephalon, Inc. ⁵ ; GlaxoSmithKline ³ ; Lundbeck ³ ; Merck, Sharp, and Dohme ³ ; National Institute of Health ³ ; Neurocrine Biosciences Inc. ³ ; Respiroics, Inc. ³ ; Sanofi-Aventis ^{1,3,5} ; Takeda Pharmaceuticals America, Inc. ^{3,5}
Eric Hollander, M.D.	Abbott Laboratories, Inc. ³ ; Lilly ³ ; National Institute of Mental Health ³ ; National Institute of Neurological Disorders and Stroke ³ ; National Institute on Drug Abuse ³ ; Neuropharm ^{1,6} ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Solvay Pharmaceuticals, Inc. ³ ; Somaxon Pharmaceuticals ³ ; U.S. Food and Drug Administration ³ ; UCB Pharma ³
Ray C. Hsiao, M.D.	Bristol-Myers Squibb Company ⁶ ; Pfizer Inc. ⁶
Rona Hu, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Pfizer Inc. ¹
Michael Y. Hwang, M.D.	Janssen Pharmaceutica Products, LP ^{1,5}
Dan V. Iosifescu, M.D.	Aspect Medical Systems ^{1,3} ; Cephalon, Inc. ^{1,3} ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ⁵
Naveed Iqbal, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3,5} ; Forest Laboratories, Inc. ³ ; Forest Pharmaceuticals, Inc. ³ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Myriad Genetics, Inc. ³ ; Otsuka America Pharmaceutical, Inc. ^{1,3,5} ; Pfizer Inc. ³ ; Sanofi-Aventis ³
Philip G. Janicak, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Neuronetics, Inc. ³ ; Pfizer Inc. ⁵ ; Solvay Pharmaceuticals, Inc. ³
Geetha Jayaram, M.D.	, ⁵ ; Bristol-Myers Squibb Company ⁵ ; Cephalon, Inc. ⁵ ; GlaxoSmithKline ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; Wyeth Pharmaceuticals ⁵
James W. Jefferson, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ^{5,6} ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ^{1,5,6} ; Healthcare Technology Systems, Inc. ^{2,4} ; Novartis Pharmaceuticals Corporation ⁵ ; Pfizer Inc. ⁵ ; Schwartz Pharma ⁵ ; Shire Pharmaceuticals Group plc. ⁵ ; Solvay Pharmaceuticals, Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Dilip V. Jeste, M.D.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Bristol-Myers Squibb Company ^{1,4} ; Eli Lilly and Company ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Institute of Mental Health ³ ; Otsuka America Pharmaceutical, Inc. ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Hadine Joffe, M.D.	Berlex Inc. ⁴ ; Eli Lilly and Company ⁵ ; GlaxoSmithKline ⁵ ; Pfizer Inc. ⁵ ; Sanofi-Aventis ⁴ ; Sepracor, Inc. ³ ; Wyeth Pharmaceuticals ⁴
Bankole Johnson, M.D.	Alkermes, Inc. ¹ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Intranasal Therapeutics, Inc. ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Ortho-McNeil Pharmaceutical, Inc. ¹ ; Sanofi-Aventis ¹ ; TransOral Pharmaceuticals, Inc. ¹
Bradley R. Johnson, M.D.	Forest Laboratories, Inc. ⁵
Joel P. Johnson, M.D.	GlaxoSmithKline ⁴
Rene Kahn	AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ¹ ; Johnson and Johnson Pharmaceutical Research and Development ⁵ ; Merck, Sharp, and Dohme ^{1,5} ; Organon Pharmaceuticals Inc. ^{1,5} ; Pfizer Inc. ^{1,5} ; Sanofi-Aventis ^{1,5}
Thomas A. Kaleita, Ph.D.	Cephalon, Inc. ^{1,3}
Ronald L. Kamm, M.D.	Pfizer Inc. ⁶
Kyle M. Kampman, M.D.	Alkermes, Inc. ³ ; Cephalon, Inc. ⁵ ; Forest Laboratories, Inc. ⁵

Presenter	Manufacturer(s)
John M. Kane, M.D.	Abbott Laboratories, Inc. ^{1,5} ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,5} ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ^{1,5} ; Janssen-Cilag ^{1,5} ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Lundbeck ¹ ; MDS Pharma Services ¹ ; MedAvante ⁶ ; Pfizer Inc. ^{1,5} ; Roche Pharmaceuticals ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth-Ayerst Laboratories ¹
Shimi Kang, M.D.	Alkermes, Inc. ^{1,5} ; AstraZeneca Pharmaceuticals LP ⁵ ; Cephalon, Inc. ⁵ ; Eli Lilly and Company ⁵ ; Janssen Pharmaceutica Products, LP ⁵
Shitij Kapur	Forest Laboratories, Inc. ⁵ ; Schwartz Pharma ⁵
Wayne J. Katon, M.D.	Eli Lilly and Company ⁴ ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ⁵ ; John A Hartford Foundation ³ ; National Institute of Mental Health ³ ; Wyeth-Ayerst Laboratories ⁴
David J. Katzelnick, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ³ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ^{3,5} ; Johnson and Johnson Pharmaceutical Research and Development ⁶ ; Lilly ⁵ ; Merck & Co., Inc. ^{1,5} ; Novartis Pharmaceuticals Corporation ^{3,5} ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ^{1,3} ; Pharmacia & Upjohn ⁵ ; Robert Wood Johnson Foundation ¹ ; Solvay Pharmaceuticals, Inc. ³ ; Wyeth Pharmaceuticals ¹
Paul E. Keck, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Memory Pharmaceuticals ¹ ; Merck & Co., Inc. ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; Neurocrine Biosciences Inc. ¹ ; Organon Pharmaceuticals Inc ³ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3} ; Pfizer Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ¹ ; Stanley Medical Research Institute ³ ; UCB Pharma ³
George A. Keepers, M.D.	Eli Lilly and Company ⁵
Samuel J. Keith, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3} ; Cyberonics, Inc. ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ³ ; Janssen-Cilag ^{1,3,5} ; Merck, Sharp, and Dohme ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Pfizer Inc. ^{1,3,5} ; Pharmacia & Upjohn ³ ; Wyeth Pharmaceuticals ³
John R. Kelsoe, M.D.	GlaxoSmithKline ⁵ ; Psynomics, Inc. ⁴
Ronald C. Kessler, Ph.D.	Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ¹ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{1,3} ; Wyeth-Ayerst Laboratories ¹
Terence A. Ketter, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Cephalon, Inc. ¹ ; Concept Therapeutics ¹ ; Eisai Inc. ³ ; Elan Pharmaceuticals, Inc. ^{1,3} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Jazz Pharmaceuticals, Inc. ¹ ; Merck & Co., Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; Pfizer Inc. ⁵ ; Shire Pharmaceuticals Group plc. ^{1,3,5} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; UCB Pharma ¹ ; Wyeth Pharmaceuticals ^{1,3}
Sabrina J. Khan, M.D.	Eli Lilly and Company ⁶ ; Merck & Co., Inc. ⁶ ; Pfizer Inc. ⁶ ; Schering-Plough Corporation ⁶
Clinton D. Kilts, Ph.D.	Forest Laboratories, Inc. ^{1,3} ; H. Lundbeck A/S ¹ ; Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; Solvay Pharmaceuticals, Inc. ¹
David G. Kingdon, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ^{4,5} ; Guilford Press ⁴ ; Janssen-Cilag ⁵ ; Pfizer Inc. ³
Herbert D. Kleber, M.D.	Alkermes, Inc. ¹ ; Reckitt-Benkiser ^{1,3}
Harold W. Koenigsberg, M.D.	Janssen Pharmaceutica Products, LP ³
George F. Koob, Ph.D.	Addex Pharmaceuticals ¹ ; Alkermes, Inc. ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Hythiam Inc. ¹
Lorin M. Koran, M.D.	Cypress Bioscience Inc. ^{1,6} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{3,5} ; Jazz Pharmaceuticals, Inc. ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Somaxon Pharmaceuticals ³
Thomas R. Kosten, M.D.	Alkermes, Inc. ¹ ; Bristol-Myers Squibb Company ¹ ; Cephalon, Inc. ¹ ; Gerson Lehman Group ¹ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,6} ; Merck, Sharp, and Dohme ¹ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ⁶
Christopher J. Kratochvil, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ¹ ; Boehringer-Ingelheim Pharmaceuticals ¹ ; Cephalon, Inc. ^{1,3} ; Eli Lilly and Company ^{1,3,5} ; McNeil Consumer Healthcare ³ ; National Institute of Mental Health ^{1,3} ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ¹ ; Shire Pharmaceuticals Group plc. ^{1,3}
K Ranga Krishnan, M.D.	Abbott Laboratories, Inc. ¹ ; Amgen, Inc ¹ ; Bristol-Myers Squibb Company ¹ ; CeNeRx ¹ ; Cyberonics, Inc. ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; H. Lundbeck A/S ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Merck & Co., Inc. ¹ ; Novartis Pharmaceuticals Corporation ³ ; NPS Pharmaceuticals ¹ ; Organon Pharmaceuticals Inc ¹ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹ ; Sepracor, Inc. ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Vela Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
Meir H. Kryger, M.D.	Cephalon, Inc. ¹ ; National Institute of Health ³ ; Takeda Pharmaceuticals America, Inc. ¹
Andrew D. Krystal, M.D.	King Pharmaceuticals, Inc. ¹ ; Merck & Co., Inc. ³ ; Neurocrine Biosciences Inc. ^{1,3} ; Neurogen Corporation ¹ ; Pfizer Inc. ^{1,3} ; Respiroics, Inc. ^{1,3} ; Sanofi-Aventis ^{1,3} ; Sepracor, Inc. ^{1,3} ; Somaxon Pharmaceuticals ^{1,3} ; Takeda Pharmaceuticals America, Inc. ¹

Presenter	Manufacturer(s)
John H. Krystal, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Janssen Research Foundation ¹ ; Merz Pharmaceuticals ¹ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ¹ ; Takeda Industries ¹
Jayashri Kulkarni, M.B.B.S.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ ; Janssen-Cilag ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; Novartis Pharmaceuticals Corporation ³ ; Organon Pharmaceuticals Inc ³ ; Sanofi/Synthelabo ³ ; Sanofi-Aventis ³ ; Servier ³ ; Stanley Medical Research Institute ³
Elisabeth J. S. Kunkel, M.D.	Forest Laboratories, Inc. ⁵
Helen H. Kyomen, M.D.	AstraZeneca Pharmaceuticals LP, Bayer Corporation; AstraZeneca Pharmaceuticals LP ¹ ; Bayer Corporation ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ¹ ; John A Hartford Foundation ³ ; Merck & Co., Inc. ¹ ; Merck & Co; National Institute on Aging ³ ; NIH Institute ³ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ^{1,3} ; Roche Pharmaceuticals ^{1,3} ; The John A. Hartford Foundation ³ ; UCB Pharma ^{1,3} ; Veterans Administration ³ ; Wyeth-Ayerst Laboratories ^{1,3}
Samuel J. Langer	Bristol-Myers Squibb Company ²
Alan Langlieb, M.D.	Eli Lilly and Company ^{3,5}
John Lauriello, M.D.	Abel Screening, Inc. ³ ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Janssen-Cilag ^{1,3,5} ; Pfizer Inc. ^{1,5}
William B. Lawson, M.D.	Abbott Laboratories, Inc. ³ ; Bristol-Myers Squibb Company ⁵ ; Janssen Pharmaceutica Products, LP ¹ ; Pfizer Inc. ¹
Arthur L. Lazarus, M.D.	AstraZeneca Pharmaceuticals LP ^{2,6}
Hochang B. Lee, M.D.	GlaxoSmithKline ^{3,5}
Steven J. Lee, M.D.	Cephalon, Inc. ⁵ ; Forest Laboratories, Inc. ⁵
Andrew C. Leon, Ph.D.	Cortex Pharmaceuticals, Inc ¹ ; Cyberonics, Inc. ¹ ; MedAvante ⁶ ; Pfizer Inc. ⁴ ; Vanda Pharmaceuticals ⁴
François Lespérance, M.D.	GlaxoSmithKline ^{3,5} ; IsodisNatura ³ ; Lundbeck ⁵ ; Servier ¹ ; Wyeth Pharmaceuticals ⁵
Stefan Leucht, M.D.	Bristol-Myers Squibb Company ^{1,5} ; Eli Lilly and Company ^{1,3,5} ; H. Lundbeck A/S ⁵ ; Janssen Pharmaceutica Products, LP ^{1,5} ; Janssen-Cilag ⁵ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,5} ; Lundbeck ⁵ ; Pfizer Inc. ⁵ ; Sanofi-Aventis ^{1,3,5}
James L. Levenson, M.D.	Eli Lilly and Company ¹
Frances R. Levin, M.D.	Alkermes, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Cephalon, Inc. ¹ ; Eli Lilly and Company ³ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ^{1,3} ; UCB Pharma ³
Petros Levounis, M.D.	Alkermes, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵ ; Cephalon, Inc. ⁵ ; Forest Laboratories, Inc. ⁵ ; Reckitt-Benkiser ⁵ ; Takeda Pharmaceuticals America, Inc. ⁵
Roberto Lewis-Fernandez, M.D.	Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ³
Jeffrey A. Lieberman, M.D.	Acadia Pharmaceuticals Inc ³ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ¹ ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Merck, Sharp, and Dohme ³ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ^{1,3} ; Pfizer Inc. ^{1,3} ; Repligen ⁴ ; Sanofi-Aventis ¹
Russell F. Lim, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵
Jean-Pierre Lindenmayer, M.D.	Alamo Pharmaceuticals ³ ; AstraZeneca Pharmaceuticals LP ³ ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Janssen-Cilag ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ³
Maria D. Llorente, M.D.	Abbott Laboratories, Inc. ¹ ; Bristol-Myers Squibb Company ⁵ ; Veterans Administration ²
Sheila M. Loboprabhu, M.D.	AstraZeneca Pharmaceuticals LP ⁵
Leslie P. Lundt, M.D.	Cephalon, Inc. ^{1,3,5} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{3,5} ; GlaxoSmithKline ³ ; Merck & Co., Inc. ³ ; Merck, Sharp, and Dohme ³ ; Pfizer Inc. ^{5,6} ; Sanofi-Aventis ^{3,5} ; Sepracor, Inc. ^{1,3,5} ; Shire Pharmaceuticals Group plc. ³ ; Takeda Pharmaceuticals America, Inc. ^{1,3,5} ; Targacept, Inc. ^{3,5} ; Wyeth Pharmaceuticals ⁵
Shari I. Lusskin, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Wyeth Pharmaceuticals ⁵
Robert B. Lydiard, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ³ ; Cephalon, Inc. ³ ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3} ; McNeil Consumer Healthcare ³ ; Novartis Pharmaceuticals Corporation ¹ ; Roche Pharmaceuticals ¹ ; Sanofi-Aventis ^{1,3} ; Wyeth Pharmaceuticals ³
Constantine G. Lyketsos, M.D.	AstraZeneca Pharmaceuticals LP ^{1,4} ; Eisai Inc. ⁴ ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{1,3} ; H. Lundbeck A/S ⁴ ; National Institute of Health ³ ; Novartis Pharmaceuticals Corporation ⁴ ; Pfizer Inc. ⁴
Kathryn J. Macdonald, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5}
Sean Mackey, M.D.	Eli Lilly and Company ⁵ ; Pfizer Inc. ⁵
Vishal Madaan, MD	GlaxoSmithKline ⁴

Presenter	Manufacturer(s)
Alan S. Maisel, M.D.	Abbott Laboratories, Inc. ³ ; Bayer Corporation ³ ; Johnson and Johnson Pharmaceutical Research and Development ⁵
Catherine L. Mancini, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Cephalon, Inc. ³ ; Eli Lilly and Company ³ ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ³ ; Pfizer Inc. ³
Christina Mangurian, M.D.	Bristol-Myers Squibb Company ⁴ ; Janssen Pharmaceutica Products, LP ³
Lauren B. Marangell, M.D.	Aspect Medical Systems ¹ ; Bristol-Myers Squibb Company ³ ; Cyberonics, Inc. ^{1,3} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ¹ ; Medtronic, Inc. ¹ ; National Institute of Health ³ ; Neuronetics, Inc. ³ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ¹ ; Stanley Medical Research Institute ³
Stephen R. Marder, M.D.	Bristol-Myers Squibb Company ¹ ; GlaxoSmithKline ¹ ; Merck, Sharp, and Dohme ¹ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ¹ ; Solvay Pharmaceuticals, Inc. ¹
John C. Markowitz, M.D.	National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³
Robert W. Marvin, M.D.	National Institute of Mental Health ³
Prakash S. Masand, M.D.	Abbott Laboratories, Inc. ^{3,5} ; Alkermes, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5,6} ; Cephalon, Inc. ^{1,3} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; Guilford Pharmaceuticals ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Jazz Pharmaceuticals, Inc. ¹ ; Organon Pharmaceuticals Inc ¹ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{1,5} ; Targacept, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3,5}
Thomas L. Matthews, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Shire Pharmaceuticals Group plc. ⁵
Helen S. Mayberg, M.D.	Advanced Neuromodulation Systems, Inc. ^{1,4} ; Cyberonics, Inc. ¹
Linda C. Mayes, M.D.	National Institute of Health ³
Thomas H. McGlashan, M.D.	Eli Lilly and Company ³
Keith McBurnett, Ph.D.	Cephalon, Inc. ³ ; McNeil Consumer Healthcare ³ ; NRP ³ ; Shire Pharmaceuticals Group plc. ³
Susan L. McElroy, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ^{3,4} ; Bristol-Myers Squibb Company ^{3,4} ; Eisai Inc. ³ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Johnson and Johnson Pharmaceutical Research and Development ⁴ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ¹ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3} ; Pfizer Inc. ^{3,4} ; Sanofi-Aventis ^{3,4} ; Somaxon Pharmaceuticals ^{3,4} ; Stanley Medical Research Institute ⁴ ; Wyeth Pharmaceuticals ¹
Joseph P. McEvoy, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{3,5} ; Eli Lilly and Company ^{3,5} ; GlaxoSmithKline ^{1,3} ; Janssen-Cilag ^{3,5} ; Organon Pharmaceuticals Inc ³ ; Otsuka America Pharmaceutical, Inc. ⁵ ; Pharmaceutical Product Development, Inc ³
Patrick D. McGorry, M.D.	AstraZeneca Pharmaceuticals LP, Janssen-Cilag ³ ; Janssen-Cilag ³
Roger S. McIntyre, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Biovail Corporation ^{1,5} ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ^{1,3,5} ; H. Lundbeck A/S ⁵ ; Janssen Pharmaceutica Products, LP ^{1,5} ; Merck & Co., Inc. ³ ; Merck, Sharp, and Dohme ³ ; Organon Pharmaceuticals Inc ^{1,5} ; Oryx Pharmaceuticals, Inc. ^{1,5} ; Pfizer Inc. ^{1,5} ; Prestwick Pharmaceuticals, Inc. ^{1,5} ; Servier ³ ; Wyeth Pharmaceuticals ^{1,3,5}
Jacqueline M. Melonas, J.D.	Professional Risk Management Services, Inc. ²
Samantha E. Meltzer-Brody, M.D.	GlaxoSmithKline ³
Matthew A. Menza, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3} ; National Institute of Mental Health ¹ ; National Institute of Neurological Disorders and Stroke ^{1,3} ; Sanofi-Aventis ^{1,3,5} ; Sepracor, Inc. ^{1,3,5} ; Takeda Pharmaceuticals America, Inc. ^{1,3,5} ; Wyeth Pharmaceuticals ³
Jonathan M. Meyer, M.D.	Bristol-Myers Squibb Company ^{1,3,4,5} ; Janssen Pharmaceutica Products, LP ^{1,4,5} ; Pfizer Inc. ^{1,3,4,5}
Eric Mick	McNeil Consumer Healthcare ^{1,3} ; National Institute of Mental Health ³ ; Shire Pharmaceuticals Group plc. ¹
Roumen V. Milev, Ph.D.	AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Biovail Corporation ¹ ; Eli Lilly and Company ^{1,3,5} ; H. Lundbeck A/S ³ ; Wyeth Pharmaceuticals ⁵ ; Wyeth-Ayerst Laboratories ⁵
Alexander L. Miller, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ³ ; InforMedix, Inc. ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Organon Pharmaceuticals Inc ³ ; Pfizer Inc. ^{1,3,5}
William R. Miller, Ph.D.	National Institute of Health ³ ; National Institute on Drug Abuse ³
Jacobo E. Mintzer, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Capital Research Companies ^{1,5} ; Eisai Inc. ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3,5} ; Janssen Pharmaceutica Products, LP ³ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3,5} ; Mitsubishi Pharmaceutical Corporation ³ ; National Institute of Health ³ ; National Institute of Mental Health ³ ; National Institute on Aging ³ ; Neurochem, Inc. ³ ; NIH Institute ³ ; Novartis Pharmaceuticals Corporation ³ ; Otsuka America Pharmaceutical, Inc. ^{1,5} ; Pfizer Inc. ^{1,3,5} ; Predix Pharmaceuticals ^{1,5} ; Sanofi-Aventis ^{1,3,5} ; Voyager Pharmaceutical Corp ³

Presenter	Manufacturer(s)
Asha S. Mishra, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵
Shaila Misri, F.R.C.P.C.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Biovail Corporation ⁵ ; GlaxoSmithKline ^{1,5} ; H. Lundbeck A/S ^{1,3,5} ; Janssen Pharmaceutica Products, LP ⁵ ; Wyeth Pharmaceuticals ^{1,3,5}
Ramin Mojtabai, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3}
Jacques Montplaisir, M.D.	Boehringer-Ingelheim Pharmaceuticals ¹ ; GlaxoSmithKline ³ ; Jazz Pharmaceuticals, Inc. ³ ; Servier ¹
Quinton E. Moss, M.D.	National Institute of Mental Health ³ ; Pfizer Inc. ⁵
David A. Mrazek, M.D.	AssureRx ⁶
Rodrigo A. Munoz, M.D.	Eli Lilly and Company ³
Philip R. Muskin, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ^{1,5} ; Cephalon, Inc. ^{1,5} ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; National Institute of Mental Health ¹ ; Otsuka America Pharmaceutical, Inc. ⁵ ; Pfizer Inc. ^{1,5}
Hugh Myrick, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ^{3,5} ; Forest Laboratories, Inc. ^{3,5} ; National Institute of Alcohol Abuse and Alcoholism ³ ; National Institute on Drug Abuse ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ³
David K. Nace, M.D.	McKesson Corporation, ² ; McKesson Corporation ²
Ziad H. Nahas, M.D.	Cyberonics, Inc. ^{1,3} ; Neuronetics, Inc. ^{1,3}
Joseph C. Napoli, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; GlaxoSmithKline ⁵ ; Pfizer Inc. ⁵
Meera Narasimhan, M.D.	Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals LP ^{3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,5} ; Forest Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ^{3,5} ; National Institute of Health ³ ; National Institute on Drug Abuse ^{3,5} ; Pfizer Inc. ⁵
Kenneth C. Nash, M.D.	Eli Lilly and Company ⁵ ; Novartis Pharmaceuticals Corporation ⁵
Henry A. Nasrallah, M.D.	Abbott Laboratories, Inc. ^{1,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Pfizer Inc. ^{1,3,5} ; Shire Pharmaceuticals Group plc. ^{1,5}
Randy J. Nelson	Merck & Co., Inc. ¹ ; National Institute of Mental Health ³
Charles B. Nemeroff, M.D.	Abbott Laboratories, Inc. ^{1,5} ; Acadia Pharmaceuticals Inc. ^{1,6} ; AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3} ; CeNeRx ⁴ ; Cyberonics, Inc. ¹ ; Cypress Bioscience Inc. ^{1,6} ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; NovaDel Pharma Inc. ⁶ ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ^{1,3,5} ; Reevax ⁴ ; UCB Pharma ¹ ; Wyeth Pharmaceuticals ^{1,3}
David N. Neubauer, M.D.	Neurocrine Biosciences Inc. ¹ ; Pfizer Inc. ¹ ; Sanofi-Aventis ^{1,5} ; Takeda Pharmaceuticals America, Inc. ^{1,5}
John W. Newcomer, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Compact Clinicals ⁴ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ^{1,3} ; Sidney R. Baer Foundation ³ ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹
D. Jeffrey Newport, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Eli Lilly and Company ^{3,5} ; GlaxoSmithKline ^{3,5} ; Janssen Pharmaceutica Products, LP ³ ; Pfizer Inc. ⁵ ; Wyeth Pharmaceuticals ³
Anthony T. Ng, M.D.	Eli Lilly and Company ⁵ ; Pfizer Inc. ⁵ ; Substance Abuse and Mental Health Services Administration/ Center for Substance Abuse Treatment ^{1,5}
Andrew A. Nierenberg, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3,5} ; Cederroth International ³ ; Cyberonics, Inc. ^{3,5} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{3,5} ; Genaissance Pharmaceuticals ¹ ; GlaxoSmithKline ^{1,3,5} ; Innapharma, Inc. ¹ ; Janssen-Cilag ¹ ; Lichtwer Pharma GmbH ³ ; Millenium Pharmaceuticals, Inc. ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ^{1,3} ; Neuronetics, Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ^{1,3,5} ; Pfizer Inc. ^{1,3} ; Sepracor, Inc. ¹ ; Shire Pharmaceuticals Group plc. ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Stanley Medical Research Institute ³ ; Sumitomo Pharmaceuticals Co., Ltd ¹ ; Wyeth Pharmaceuticals ^{1,3,5}
Andrei Novac, M.D.	Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ⁵ ; Pfizer Inc. ⁵
Keith H. Nuechterlein, Ph.D.	Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health, Janssen Pharmaceutica Products, LP ³
Edward V. Nunes, M.D.	Alkermes, Inc. ^{1,5} ; Cephalon, Inc. ⁵
H. George Nurnberg, M.D.	Abbott Laboratories, Inc. ^{3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; GlaxoSmithKline ^{1,5} ; Liplha Pharma ³ ; Parke-Davis ³ ; Pfizer Inc. ^{1,3,5} ; Wyeth Pharmaceuticals ^{3,5}

Presenter	Manufacturer(s)
David J. Nutt, D.M.	Asahi ¹ ; Cephalon, Inc. ⁵ ; Cypress Bioscience Inc. ^{1,5} ; Eli Lilly and Company ^{1,5} ; Esteve ¹ ; GlaxoSmithKline ^{1,3,5,6} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Lundbeck ^{3,5} ; MDS Pharma Services ^{1,3,5} ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; Organon Pharmaceuticals Inc. ^{1,3,5} ; Passion for Life ¹ ; Pfizer Inc. ^{1,3,5} ; Pharmacia & Upjohn ^{1,5} ; Reckitt-Benkiser ⁵ ; Servier ³ ; Takeda Pharmaceuticals America, Inc. ^{1,5} ; Therasci ¹ ; Wyeth Pharmaceuticals ^{3,5} ; Yamanouchi ³
Mary B. O'Malley, M.D.	Cephalon, Inc. ^{3,5} ; GlaxoSmithKline ³ ; Merck & Co., Inc. ³ ; Neurocrine Biosciences Inc. ⁵ ; Pfizer Inc. ⁵ ; Sepracor, Inc. ⁵
Stephanie O'Malley, Ph.D.	Alkermes, Inc. ³
Cheryl A. Oncken, M.D.	National Institute on Drug Abuse ³ ; Pfizer Inc. ^{1,3}
Lewis A. Opler, M.D.	Multi-Health Systems, Inc. ⁴
Urban p. Ösby, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,5} ; Eli Lilly and Company ^{1,5} ; National Alliance for Research in Schizophrenia and Depression ³ ; Pfizer Inc. ^{1,5}
David W. Oslin, M.D.	NIH Institute, Robert Wood Johnson Foundation ³
Michael J. Ostacher, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; GlaxoSmithKline ⁵ ; Janssen Pharmaceutica Products, LP ⁵ ; Pfizer Inc. ⁵
Sagar V. Parikh, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3} ; Biovail Corporation ^{1,3} ; Eli Lilly and Company ³ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ ; Novartis Pharmaceuticals Corporation ³ ; Wyeth Pharmaceuticals ^{1,3}
Lawrence T. Park, M.D.	Abbott Laboratories, Inc. ³ ; Bristol-Myers Squibb Company ³ ; Janssen Pharmaceutica Products, LP ³
Joseph J. Parks	Abbott Laboratories, Inc. ³ ; Comprehensive Neurosciences Incorporated ¹ ; Medical Letters and Sciences ⁵
Amita R. Patel, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Cyberonics, Inc. ⁵ ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ⁵ ; Novartis Pharmaceuticals Corporation ⁵ ; Sanofi-Aventis ⁵ ; Takeda Pharmaceuticals America, Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Martin P. Paulus, M.D.	GlaxoSmithKline ¹
Roy H. Perlis, Ph.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Pfizer Inc. ¹
Eric D. Peselow, M.D.	Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ⁵ ; Pfizer Inc. ⁵
Francois C. Petitjean, M.D.	Bristol-Myers Squibb Company ^{1,5} ; Janssen-Cilag ^{1,5} ; Sanofi-Aventis ¹
Barbara A. Phillips, M.D.	Boehringer-Ingelheim Pharmaceuticals ¹ ; GlaxoSmithKline ¹
Katharine A. Phillips, M.D.	American Psychiatric Press ⁴ ; Forest Laboratories, Inc. ³ ; National Institute of Mental Health ³ ; UCB Pharma ³ ; Pfizer Inc. ⁵
Edmond H. Pi, M.D.	Academy of Managed Care Pharmacy (AMCP) Horizons, LLC ⁴ ; American Psychiatric Press ⁴ ; Atlantic Philanthropies ³ ; Bimark Medical Education ⁴ ; Cardinal Health, Inc. ⁴ ; Cisco Systems ¹ ; Columbia University ² ; Community Care Behavioral Health Organization/UPMC Health Plan ¹ ; Comprehensive NeuroScience, Inc., Medical Information Technologies ⁴ ; Current Opinion in Psychiatry/Lippincott, William and Wilkins ⁴ ; National Institute of Child Health and Human Development ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; New York-Presbyterian Hospital ² ; RAND Corporation ² ; Raymond John Wean Foundation ³ ; Substance Abuse and Mental Health Services Administration/ Center for Substance Abuse Treatment ³ ; The Heinz Endowments ³ ; The John A. Hartford Foundation ³ ; The Robert Wood Johnson Foundation ³ ; Veterans Administration ³
Mark H. Pollack, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Cephalon, Inc. ^{1,3} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; National Institute on Drug Abuse ³ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ¹ ; Sepracor, Inc. ^{1,3} ; UCB Pharma ^{1,3} ; Wyeth Pharmaceuticals ^{1,3,5}
Bruce G. Pollock, M.D.	Forest Laboratories, Inc. ^{1,5} ; Janssen Pharmaceutica Products, LP ³ ; Lundbeck ^{1,5} ; National Institute of Mental Health ³
Marc N. Potenza, M.D.	Gerson Lehman Group ¹ ; GlaxoSmithKline ¹ ; National Institute of Alcohol Abuse and Alcoholism ¹ ; National Institute of Child Health and Human Development ¹ ; National Institute of Neurological Disorders and Stroke ¹ ; National Institute on Drug Abuse ^{1,3} ; NIH Institute ^{1,3} ; Somaxon Pharmaceuticals ¹
Annelle B. Primm, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Eli Lilly and Company ¹ ; Pfizer Inc. ¹
Jefferson B. Prince, M.D.	McNeil Consumer Healthcare, Shire Pharmaceuticals Group plc. ¹
Andres J. Pumariega, M.D.	Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ⁵
Paul M. Ramirez, Ph.D.	Multi-Health Systems, Inc. ⁴

Presenter	Manufacturer(s)
Mark H. Rapaport, M.D.	Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals LP ³ ; BrainCells, Inc. ¹ ; Cyberonics, Inc. ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3,5,6} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ^{1,3} ; National Institute on Drug Abuse ¹ ; Neurocrine Biosciences Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; Pfizer Inc. ^{1,3,5} ; Pharmacia & Upjohn ³ ; Roche Pharmaceuticals ¹ ; Sanofi-Aventis ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Stanley Medical Research Institute ³ ; Sumitomo Pharmaceuticals Co., Ltd ¹ ; UCB Pharma ³ ; Wyeth Pharmaceuticals ^{1,3,5}
Natalia L. Rasgon, M.Ed.	Abbott Laboratories, Inc. ^{1,3,5} ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ^{1,5} ; Novartis Pharmaceuticals Corporation ⁵ ; Pfizer Inc. ⁵ ; Wyeth Pharmaceuticals ^{1,5}
Lawrence P. Reagan, Ph.D.	Servier ^{1,3}
William E. Reichman, M.D.	Eisai Inc. ³ ; Forest Laboratories, Inc. ^{1,3,5} ; Fujisawa Pharmaceutical, Co. ³ ; Myriad Genetics, Inc. ³ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,5} ; Pfizer Inc. ⁵ ; Sanofi-Aventis ³ ; Takeda Pharmaceuticals America, Inc. ³
John A. Renner, M.D.	Alkermes, Inc. ⁵ ; Cephalon, Inc. ⁵ ; Johnson & Johnson ⁶ ; Reckitt-Benkiser ⁵ ; Shire Pharmaceuticals Group plc. ¹
Perry F. Renshaw, M.D.	Eli Lilly and Company ³ ; GlaxoSmithKline ¹ ; Kyowa Hakko ¹ ; Novartis Pharmaceuticals Corporation ¹
Roy O. Resnikoff, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ⁴ ; Eli Lilly and Company ⁴ ; Forest Laboratories, Inc. ⁴ ; GlaxoSmithKline ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴
Victor I. Reus, M.D.	Nabi Pharmaceuticals ³
Charles F. Reynolds, M.D.	Forest Laboratories, Inc. ³
Michelle B. Riba, M.D.	Eli Lilly and Company ¹ ; GlaxoSmithKline ¹ ; Pfizer Inc. ¹
Steven Richeimer, M.D.	Merck & Co., Inc. ⁵ ; Pfizer Inc. ⁵ ; Purdue Pharma L.P. ⁵
Elliott Richelson, M.D.	Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ³ ; Neuronetics, Inc. ³ ; Pfizer Inc. ⁵ ; Sanofi-Aventis ¹ ; Somaxon Pharmaceuticals ¹
Paula D. Riggs, M.D.	Eli Lilly and Company ³ ; McNeil Consumer Healthcare ³ ; National Institute on Drug Abuse ³ ; Shire Pharmaceuticals Group plc. ^{1,5}
Trevor Robbins, Ph.D.	CeNeS Pharmaceuticals ⁶ ; Cephalon, Inc. ^{1,5} ; Cortex Pharmaceuticals, Inc. ^{1,5} ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Pfizer Inc. ³ ; Roche Pharmaceuticals ^{1,5}
Delbert G. Robinson, M.D.	Bristol-Myers Squibb Company ³ ; Janssen Pharmaceutica Products, LP ³
Robert G. Robinson, M.D.	Avanir Pharmaceuticals ¹
Steven P. Roose, M.D.	Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ¹ ; Wyeth Pharmaceuticals ^{1,3}
Jerrold F. Rosenbaum	Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ¹ ; Roche Pharmaceuticals ¹ ; Sanofi-Aventis ¹ ; Sepracor, Inc. ¹
Cherise Rosen, Ph.D.	National Institute of Mental Health ³
Robert Rosenheck, M.D.	AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Janssen Pharmaceutica Products, LP; Wyeth Pharmaceuticals
Richard N. Rosenthal, M.D.	Alkermes, Inc. ¹ ; Cephalon, Inc. ¹ ; Forest Laboratories, Inc. ¹
A. John Rush, M.D.	Advanced Neuromodulation Systems, Inc. ¹ ; Best Practice Project Management, Inc. ¹ ; Bristol-Myers Squibb Company ¹ ; Cyberonics, Inc. ^{1,5} ; Eli Lilly and Company ¹ ; Forest Laboratories, Inc. ^{1,5} ; Gerson Lehman Group ¹ ; GlaxoSmithKline ^{1,5} ; Guilford Publications ⁴ ; Healthcare Technology Systems, Inc ⁴ ; Jazz Pharmaceuticals, Inc. ¹ ; Merck & Co., Inc. ^{1,5} ; National Institute of Mental Health ³ ; Neuronetics, Inc. ¹ ; NIH Institute ³ ; Novartis Pharmaceuticals Corporation ¹ ; Ono Pharmaceuticals, Inc. ¹ ; Organon Pharmaceuticals Inc ¹ ; Personality Disorder Research Corporation ¹ ; Pfizer Inc. ⁶ ; Robert Wood Johnson Foundation ³ ; Stanley Medical Research Institute ³ ; Urban Institute ¹ ; Wyeth Pharmaceuticals ¹ ; Wyeth-Ayerst Laboratories ¹
Deirdre M. Ryan, F.R.C.P.C.	Wyeth Pharmaceuticals ³
Abe M. Rychik, J.D.	Professional Risk Management Services, Inc. ⁴
Perminder Sachdev, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Pfizer Inc. ⁵
Gary S. Sachs, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,5} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Memory Pharmaceuticals ¹ ; Merck & Co., Inc. ¹ ; Merck, Sharp, and Dohme ¹ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Otsuka America Pharmaceutical, Inc. ^{1,5} ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ³ ; Shire Pharmaceuticals Group plc. ¹ ; Stanley Medical Research Institute ³ ; Wyeth Pharmaceuticals ^{1,3,5}
Ihsan M. Salloum, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; Alkermes, Inc. ³ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Cephalon, Inc. ¹ ; Drug Abuse Sciences, Inc ³ ; Forest Laboratories, Inc. ¹ ; Liplha Pharma ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Oy Central Pharma ³

DISCLOSURE INDEX

Presenter	Manufacturer(s)
Jitender Sareen, M.D.	GlaxoSmithKline ⁵
Norman H. Sartorius, M.D.	Eli Lilly and Company ¹ ; Janssen-Cilag ¹ ; Lilly ¹ ; Lundbeck ¹ ; Wyeth Pharmaceuticals ¹
Ayal Schaffer, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5} ; Biovail Corporation ⁵ ; Eli Lilly and Company ^{1,5} ; H. Lundbeck A/S ⁵ ; Sanofi-Aventis ³ ; Servier ³
Alan F. Schatzberg, M.D.	Abbott Laboratories, Inc. ¹ ; Aventis Pharmaceuticals, Inc. ¹ ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ^{1,3} ; Innapharma, Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Neuronetics, Inc. ¹ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ^{1,6} ; Somaxon Pharmaceuticals ¹ ; Somerset Pharmaceuticals Inc. ^{1,3} ; Wyeth Pharmaceuticals ^{1,3}
Thomas Schlaepfer	Cyberonics, Inc. ³ ; Medtronics, Inc. ³
Lon S. Schneider, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ¹ ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3} ; Lundbeck ⁵ ; Myriad Genetics, Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Pfizer Inc. ³ ; Wyeth Pharmaceuticals ¹
Nina R. Schooler, Ph.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ^{1,3} ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Merck & Co., Inc. ¹ ; National Institute of Mental Health ¹ ; National Institute on Drug Abuse ¹ ; Organon Pharmaceuticals Inc ¹ ; Pfizer Inc. ^{1,3} ; Vanda Pharmaceuticals ¹
S. Charles Schulz, M.D.	Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Eli Lilly and Company ^{1,3,5}
Gary J. Schummer, Ph.D.	A.D.D. Treatment Centers ²
Michael A. Schwartz, M.D.	AstraZeneca Pharmaceuticals LP ^{3,5} ; Bristol-Myers Squibb Company ^{3,5} ; Cephalon, Inc. ⁵ ; Eli Lilly and Company ⁵ ; Janssen Pharmaceutica Products, LP ³ ; Johnson and Johnson Pharmaceutical Research and Development ³ ; Takeda Pharmaceuticals America, Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Thomas L. Schwartz, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ^{3,5} ; Cephalon, Inc. ^{3,5} ; Cyberonics, Inc. ^{3,5} ; Forest Laboratories, Inc. ³ ; GlaxoSmithKline ⁵ ; Jazz Pharmaceuticals, Inc. ^{3,5} ; Pfizer Inc. ⁵ ; Sanofi-Aventis ⁵ ; Takeda Pharmaceuticals America, Inc. ⁵ ; Wyeth Pharmaceuticals ^{1,5}
Jan L. Scott, M.D.	AstraZeneca Pharmaceuticals LP ^{3,5} ; Eli Lilly and Company ^{3,5} ; Janssen-Cilag ⁵ ; Otsuka America Pharmaceutical, Inc. ⁵ ; Sanofi-Aventis ⁵
David S. Shannahoff-Khalsa	W.W. Norton & Co., Inc. ⁴
Zafar Sharif, M.D.	Bristol-Myers Squibb Company, Janssen Pharmaceutica Products, LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Janssen Pharmaceutica Products, LP ⁵
M. Katherine Shear, M.D.	Forest Laboratories, Inc. ³ ; Pfizer Inc. ¹
David V. Sheehan, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; Alexza MDC ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Avera Pharmaceuticals, Inc. ¹ ; Bristol-Myers Squibb Company ^{1,3,5} ; Cephalon, Inc. ^{1,3} ; Cortex Pharmaceuticals, Inc. ¹ ; Cypress Bioscience Inc. ¹ ; Eisai Inc. ³ ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Jazz Pharmaceuticals, Inc. ^{1,3} ; Layton Biosciences, Inc. ^{1,6} ; Mead Johnson ^{3,5} ; Medical Outcome Systems, Inc. ⁶ ; Merck & Co., Inc. ^{1,3,5} ; Novartis Pharmaceuticals Corporation ³ ; Novo Nordisk Pharmaceuticals, Inc. ⁵ ; Organon Pharmaceuticals Inc ^{1,5} ; Ortho-McNeil Pharmaceutical, Inc. ⁵ ; Parke-Davis ^{3,5} ; Pfizer Inc. ^{1,3,5} ; Pharmacia & Upjohn ^{1,5} ; Roche Pharmaceuticals ^{1,5} ; Sanofi-Aventis ¹ ; Schering-Plough Corporation ⁵ ; Shire Pharmaceuticals Group plc. ¹ ; Solvay Pharmaceuticals, Inc. ^{1,5} ; TAP Pharmaceuticals, Inc. ^{1,3,5} ; Warner Chilcott PLC ^{3,5} ; Wyeth Pharmaceuticals ^{1,3,5} ; ZARS Pharma ¹
Richard C. Shelton	Abbott Laboratories, Inc. ^{3,5} ; AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ^{3,5} ; GlaxoSmithKline ^{3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ³ ; Solvay Pharmaceuticals, Inc. ⁵ ; Wyeth Pharmaceuticals ^{3,5}
Larry J. Siever, M.Ed.	Eli Lilly and Company ^{1,3}
Daphne Simeon, M.D.	National Institute of Health ³
Gregory E. Simon, M.D.	Bristol-Myers Squibb Company ¹ ; Wyeth Pharmaceuticals ¹
Naomi M. Simon, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Cephalon, Inc. ³ ; Eli Lilly and Company ³ ; Forest Laboratories, Inc. ^{3,5} ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Pfizer Inc. ^{3,5} ; Sepracor, Inc. ³ ; UCB Pharma ³
Kelly H. Skelton, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Pfizer Inc. ⁵
Andrew E. Skodol, M.D.	National Institute of Mental Health ³
Gary W. Small	Abbott Laboratories, Inc. ^{1,5} ; Brainstorming Co. ¹ ; Dakim ^{1,6} ; Eisai Inc. ^{1,5} ; Forest Laboratories, Inc. ^{1,5} ; GlaxoSmithKline ³ ; Memory Fitness Institute ^{1,5} ; Myriad Genetics, Inc. ^{1,5} ; Novartis Pharmaceuticals Corporation ^{1,5} ; Ortho-McNeil Pharmaceutical, Inc. ^{1,5} ; Pfizer Inc. ^{1,5} ; Siemens ^{1,4}
Thomas E. Smith, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ^{1,5} ; Pfizer Inc. ⁵

Presenter	Manufacturer(s)
Jordan W. Smoller, M.D.	Roche Pharmaceuticals ¹
Mark Snowden, M.D.	Pfizer Inc. ⁵
Claudio N. Soares, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Berlex Inc. ⁵ ; Eli Lilly and Company ³ ; GlaxoSmithKline ^{1,5} ; H. Lundbeck A/S ^{1,5} ; National Alliance for Research in Schizophrenia and Depression ³ ; Sepracor, Inc. ¹ ; Wyeth Pharmaceuticals ⁵
Mary Solanto, Ph.D.	McNeil Consumer Healthcare ¹ ; Shire Pharmaceuticals Group plc. ¹
Wesley E. Sowers	Deerfield Behavioral Health, Inc. ¹
Thomas J. Spencer, M.D.	Eli Lilly and Company ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; McNeil Consumer Healthcare ^{1,3,5} ; National Foundation for Mental Health ³ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; Pfizer Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ^{1,3,5} ; Wyeth Pharmaceuticals ⁵
Joyce Sprafkin, Ph.D.	Checkmate Plus ⁶
Stephen M. Stahl, M.Div.	Acadia Pharmaceuticals Inc ¹ ; Asahi ¹ ; AstraZeneca Pharmaceuticals LP ^{1,3} ; Avera Pharmaceuticals, Inc. ¹ ; Biovail Corporation ^{1,3} ; Bristol-Myers Squibb Company ^{1,3} ; Cephalon, Inc. ^{1,3} ; Cyberonics, Inc. ^{1,3} ; Cypress Bioscience Inc. ^{1,3} ; Eli Lilly and Company ^{1,3} ; EPIX ¹ ; Fabre Kramer Pharmaceuticals Inc. ¹ ; Forest Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; H. Lundbeck A/S ¹ ; Innapharma, Inc. ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Neurocrine Biosciences Inc. ^{1,3} ; Neuromolecular Inc. ¹ ; Neuronetics, Inc. ¹ ; NovaDel Pharma Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc ^{1,3} ; Otsuka America Pharmaceutical, Inc. ¹ ; Pfizer Inc. ^{1,3,5} ; Sanofi/Synthelabo ¹ ; Sanofi-Aventis ¹ ; Schering-Plough Corporation ¹ ; Sepracor, Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ¹ ; Somaxon Pharmaceuticals ^{1,3} ; Tetrigenex Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3} ; Wyeth-Ayerst Laboratories ³
Jodi E. Star, M.D.	AstraZeneca Pharmaceuticals LP ⁵
Murray B. Stein, M.D.	AstraZeneca Pharmaceuticals LP ¹ ; Avera Pharmaceuticals, Inc. ¹ ; Cephalon, Inc. ¹ ; Eli Lilly and Company ^{1,3} ; F. Hoffmann-La Roche & Co. ^{1,3} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ³ ; Jazz Pharmaceuticals, Inc. ¹ ; National Institute of Mental Health ³ ; Solvay Pharmaceuticals, Inc. ¹ ; UCB Pharma ¹
Altha J. Stewart, M.D.	Pfizer Inc. ¹
Paul Stiles, Ph.D.	Eli Lilly and Company ³
Keith R. Stowell, M.D.	GlaxoSmithKline ⁴ ; Somaxon Pharmaceuticals ⁴
Zachary N. Stowe, M.D.	Bristol-Myers Squibb Company ^{1,5} ; Eli Lilly and Company ⁵ ; GlaxoSmithKline ^{1,3,5} ; Pfizer Inc. ^{3,5} ; Wyeth Pharmaceuticals ^{1,3,5}
Eric C. Strain, M.D.	Alkermes, Inc. ¹ ; GlaxoSmithKline ¹ ; National Institute on Drug Abuse ³ ; Reckitt-Benkiser ⁵ ; Schering-Plough Corporation ⁵ ; Shire Pharmaceuticals Group plc. ¹ ; Substance Abuse and Mental Health Services Administration/ Center for Substance Abuse Treatment ¹ ; Titan Pharmaceutical, Inc ¹
Katharine A. Stratigos, M.D.	Shire Pharmaceuticals Group plc. ⁴
Thomas S. Stroup, M.D.	Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Pfizer Inc. ¹
Donna M. Sudak, M.D.	LWW - Author ⁴
Patricia Suppes, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3} ; JDS Pharmaceuticals ^{1,3} ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Ortho-McNeil Pharmaceutical, Inc. ¹ ; Pfizer Inc. ^{1,3} ; Shire Pharmaceuticals Group plc. ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Stanley Medical Research Institute ³ ; UCB Pharma ¹ ; Wyeth Pharmaceuticals ³
Alan C. Swann, M.D.	Abbott Laboratories, Inc. ^{1,3,5} ; AstraZeneca Pharmaceuticals LP ¹ ; CIBA ³ ; Eli Lilly and Company ^{3,5} ; GlaxoSmithKline ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Ortho-McNeil Pharmaceutical, Inc. ^{1,5} ; Parke-Davis ⁵ ; Pfizer Inc. ^{3,5} ; Shire Pharmaceuticals Group plc. ^{1,3} ; UCB Pharma ³
Holly A. Swartz, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ^{4,5} ; Eli Lilly and Company ¹ ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ⁵
Marvin S. Swartz, M.D.	Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ¹ ; Pfizer Inc. ^{1,5}
Robert M. Swift, M.D.	Alkermes, Inc. ¹ ; Cephalon, Inc. ⁵ ; Drug Abuse Sciences, Inc ³ ; Forest Laboratories, Inc. ^{1,3,5} ; National Institute of Alcohol Abuse and Alcoholism ³ ; Ortho-McNeil Pharmaceutical, Inc. ^{1,3} ; Oy Contral Pharma ³ ; Pfizer Inc. ^{1,3}
Carol A. Tamminga, M.D.	Acadia Pharmaceuticals Inc ^{1,3} ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; National Institute of Mental Health ^{1,3} ; Neurogen Corporation ¹ ; Stanley Medical Research Institute ³
Rajiv Tandon, M.D.	AstraZeneca Pharmaceuticals LP ⁴ ; Bristol-Myers Squibb Company ⁴ ; Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; National Institute of Mental Health ⁴ ; Otsuka America Pharmaceutical, Inc. ⁴ ; Pfizer Inc. ⁴
Pierre N. Tariot, M.D.	Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3} ; Eisai Inc. ^{1,5} ; Elan Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ^{1,3} ; Forest Laboratories, Inc. ^{1,3,5}

Presenter	Manufacturer(s)
	GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ¹ ; Merck & Co., Inc. ^{1,3} ; Merck, Sharp, and Dohme ¹ ; Mitsubishi Pharmaceutical Corporation ^{1,3} ; Myriad Genetics, Inc. ^{1,3} ; National Institute of Mental Health ³ ; National Institute on Aging ³ ; Neurochem, Inc. ^{1,3} ; Ono Pharmaceuticals, Inc. ^{1,3} ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ^{1,3} ; Schwabe ¹ ; Takeda Pharmaceuticals America, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3}
Janet Taylor, M.D.	AstraZeneca Pharmaceuticals LP ⁵
Humberto Temporini, M.D.	Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals LP ⁵ ; Pfizer Inc. ⁵
Michael E. Thase, M.D.	AstraZeneca Pharmaceuticals LP ^{1,5} ; Bristol-Myers Squibb Company ^{1,5} ; Cephalon, Inc. ¹ ; Cyberonics, Inc. ^{1,5} ; Eli Lilly and Company ^{1,5} ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ^{1,5} ; Janssen Pharmaceutica Products, LP ¹ ; Neuronetics, Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc. ^{1,5} ; Pfizer Inc. ¹ ; Sanofi-Aventis ⁵ ; Sepracor, Inc. ¹ ; Shire Pharmaceuticals Group plc. ¹ ; Wyeth Pharmaceuticals ^{1,5}
Jean M. Thomas, M.D.	National Institute of Mental Health ³
Martin G. Tracy, J.D.	Professional Risk Management Services, Inc. ²
Anton C. Trinidad, M.D.	McNeil Consumer Healthcare ³ ; Pfizer Inc. ⁵ ; Sanofi-Aventis ³ ; Wyeth Pharmaceuticals ³
Madhukar H. Trivedi, M.D.	Abbott Laboratories, Inc. ³ ; Bayer Corporation ³ ; Bristol-Myers Squibb Company ^{1,3,5} ; Cephalon, Inc. ³ ; Cyberonics, Inc. ^{1,5} ; Eli Lilly and Company ^{1,3,5} ; Forest Laboratories, Inc. ^{1,3,5} ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3,5} ; Mead Johnson ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Organon Pharmaceuticals Inc. ^{1,3,5} ; Parke-Davis ³ ; Pfizer Inc. ^{1,3,5} ; Pharmacia & Upjohn ^{1,3,5} ; Predix Pharmaceuticals ³ ; Sepracor, Inc. ^{1,5} ; Solvay Pharmaceuticals, Inc. ^{1,3,5} ; Wyeth Pharmaceuticals ^{1,3,5}
Paula T. Trzepacz, M.D.	Eli Lilly and Company ^{2,6}
Guochuan E. Tsai, M.D.	Prestwick Pharmaceuticals, Inc. ⁴
Phebe M. Tucker, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Cephalon, Inc. ³ ; Forest Laboratories, Inc. ^{1,5} ; GlaxoSmithKline ³ ; Ortho-McNeil Pharmaceutical, Inc. ³ ; Pfizer Inc. ^{3,5} ; Wyeth Pharmaceuticals ^{1,3}
Douglas Turkington, M.D.	AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Janssen-Cilag ^{3,5}
Himanshu P. Upadhyaya	Abbott Laboratories, Inc. ⁵ ; Cephalon, Inc. ³ ; Eli Lilly and Company ³ ; Shire Pharmaceuticals Group plc. ¹
Jim Van Os, M.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ³ ; GlaxoSmithKline ³
Donna Vanderpool, J.D.	Professional Risk Management Services, Inc. ²
Sanjay M. Vaswani, M.D.	Abbott Laboratories, Inc. ¹ ; Eli Lilly and Company ⁵ ; Forest Laboratories, Inc. ¹ ; GlaxoSmithKline ⁵ ; Pfizer Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Dawn I. Velligan, Ph.D.	AstraZeneca Pharmaceuticals LP ^{1,3,4,5} ; Bristol-Myers Squibb Company ^{1,4} ; Eli Lilly and Company ^{1,3} ; InforMedix, Inc. ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,4,5} ; Pfizer Inc. ^{1,3,4,5}
Marcia L. Verduin, M.D.	Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ³ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ ; National Institute on Drug Abuse ³ ; Office of Research on Women's Health ³
Eduard Vieta, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; GlaxoSmithKline ^{1,3,5} ; H. Lundbeck A/S ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Janssen-Cilag ^{1,3,5} ; Johnson and Johnson Pharmaceutical Research and Development ^{1,3} ; Lundbeck ¹ ; Merck, Sharp, and Dohme ¹ ; NIH Institute ¹ ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; Organon Pharmaceuticals Inc. ¹ ; Otsuka America Pharmaceutical, Inc. ^{1,3,5} ; Pfizer Inc. ^{1,3,5} ; Sanofi-Aventis ^{1,3,5} ; Servier ^{1,3,5} ; Stanley Medical Research Institute ³ ; UCB Pharma ¹
Suzanne E. Vogel-Scibilia, M.D.	Abbott Laboratories, Inc. ⁵ ; AstraZeneca Pharmaceuticals LP ⁵ ; Bristol-Myers Squibb Company ⁵ ; Forest Laboratories, Inc. ⁵ ; Pfizer Inc. ⁵
Mark S. Wallace, M.D.	Abbott Laboratories, Inc. ¹ ; Johnson and Johnson Pharmaceutical Research and Development ¹ ; Pfizer Inc. ⁵ ; Roche Pharmaceuticals ¹
B. Timothy Walsh, M.D.	Abbott Laboratories, Inc. ³ ; Eli Lilly and Company ³ ; GlaxoSmithKline ³ ; Ortho-McNeil Pharmaceutical, Inc. ³
Peter J. Weiden, M.D.	AstraZeneca Pharmaceuticals LP ^{1,3,5} ; Bristol-Myers Squibb Company ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Johnson and Johnson Pharmaceutical Research and Development ⁵ ; Organon Pharmaceuticals Inc. ¹ ; Pfizer Inc. ^{1,3,5} ; Shire Pharmaceuticals Group plc. ⁵ ; Vanda Pharmaceuticals ¹
Elyse D. Weiner, M.D.	Pfizer Inc. ⁵ ; Wyeth Pharmaceuticals ⁵
Daniel Weintraub	Avanir Pharmaceuticals ¹
Sidney Weissman	Eli Lilly; Merck; Organon
Margaret D. Weiss, M.D.	Cephalon, Inc. ^{1,3,5} ; Eli Lilly and Company ^{1,3,5} ; Janssen Pharmaceutica Products, LP ^{1,3,5} ; Novartis Pharmaceuticals Corporation ^{1,3,5} ; Purdue Pharma L.P. ^{1,3,5} ; Shire Pharmaceuticals Group plc. ^{1,3,5}
Roger D. Weiss, Ph.D.	Abbott Laboratories, Inc. ⁵ ; Alkermes, Inc. ¹ ; Ortho-McNeil Pharmaceutical, Inc. ³

Presenter	Manufacturer(s)
Joyce C. West, Ph.D.	AstraZeneca Pharmaceuticals LP ³ ; Bristol-Myers Squibb Company ³ ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ ; National Institute of Mental Health ³ ; Substance Abuse and Mental Health Services Administration/ Center for Substance Abuse Treatment ³ ; Wyeth Pharmaceuticals ³
Timothy E. Wilens, M.D.	Abbott Laboratories, Inc. ¹ ; Eli Lilly and Company ^{3,5} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; National Institute of Mental Health ¹ ; National Institute on Drug Abuse ³ ; NeuroSearch A/S ³ ; Novartis Pharmaceuticals Corporation ⁵ ; Ortho-McNeil Pharmaceutical, Inc. ^{3,5} ; Pfizer Inc. ¹ ; Saegis ¹ ; Sanofi-Aventis ¹ ; Shire Pharmaceuticals Group plc. ^{3,5}
Jeffery N. Wilkins, M.D.	Alkermes, Inc. ^{1,3} ; CME LLC ¹ ; Forest Laboratories, Inc. ³ ; Hythiam Inc. ^{1,3}
Janet B.W. Williams, D.S.W.	American Psychiatric Press ⁴ ; Columbia University ² ; MedAvante, Inc. ¹
Solomon S. Williams, M.D.	Boehringer-Ingelheim Pharmaceuticals ²
M.E. Jan Wise, M.B.Ch.B.	Bristol-Myers Squibb Company ⁵ ; Eli Lilly and Company ⁵
Thomas N. Wise, M.D.	Eli Lilly and Company ¹
Jesse H. Wright III, M.D.	Mindstreet ⁴ ; Pfizer, GlaxoSmithKline ⁵
Aysegul Yildiz-Yesiloglu, M.D.	AstraZeneca Pharmaceuticals LP ³ ; GlaxoSmithKline ³ ; Janssen-Cilag ³ ; Pfizer Inc. ³
Monique Yohanan, M.D.	Elan Pharmaceuticals, Inc. ⁴ ; Johnson and Johnson Pharmaceutical Research and Development ⁶
M. Scott Young, Ph.D.	Eli Lilly and Company ³
Mary C. Zanarini, Ed.D.	Eli Lilly and Company ^{1,3}
Phyllis C. Zee, M.D.	Kyowa Pharmaceuticals ³ ; Neurocrine Biosciences Inc. ¹ ; Pfizer Inc. ¹ ; Sanofi-Aventis ^{1,5} ; Takeda Pharmaceuticals America, Inc. ^{1,5}
Mark Zimmerman, M.D.	Bristol-Myers Squibb Company ⁵ ; GlaxoSmithKline ⁵ ; Wyeth Pharmaceuticals ⁵
Sidney Zisook, M.D.	Aspect Medical Systems ³ ; Forest Laboratories, Inc. ⁵ ; GlaxoSmithKline ^{1,5} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Health ³ ; National Institute of Mental Health ³ ; PamLab ³
Joseph Zohar, M.D.	Lundbeck ³ ; Pfizer Inc. ³
Edward Zuzarte, M.D.	Pfizer Inc. ⁵